Korsana Biosciences (KRSA) vs Stoke Therapeutics (STOK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Korsana Biosciences (KRSA) has outperformed Stoke Therapeutics (STOK) over the past year, gaining 90.0% versus a loss of 21.5%. Over five years, STOK leads with a +1.8% price change compared with -91.1% for KRSA. Stoke Therapeutics is the larger company by market cap ($1.55 billion vs $1.53 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRSA | STOK |
|---|---|---|
| Share price | $33.51 | $23.95 |
| Market cap | $1.53B | $1.55B |
| 1-day change | +6.37% | -1.40% |
| YTD return | +276.94% | -24.54% |
| 1-year return | +89.97% | -21.48% |
| 5-year return | -91.10% | +1.83% |
| EPS (TTM) | $-7.07 | $-3.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $59.36 | $40.22 |
| 52-week low | $7.19 | $20.32 |
| Distance from 52-week high | -43.55% | -40.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +31.30% | +93.99% |
| Average volume | 32.06K | 855.13K |
| Shares outstanding | 45.54M | 64.53M |
| Employees | 19 | 170 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRSA has outperformed STOK by 111.4 percentage points over the past year.
About Korsana Biosciences
KRSA stock →Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Stoke Therapeutics
STOK stock →Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees
KRSA vs STOK FAQ
Which is bigger, Korsana Biosciences or Stoke Therapeutics?
Stoke Therapeutics (STOK) is larger, with a market capitalization of $1.55B compared with $1.53B for Korsana Biosciences (KRSA).
Which stock has performed better over the past year, KRSA or STOK?
KRSA returned +89.97% over the past 12 months, compared with -21.48% for STOK (price return, excluding dividends). Past performance does not predict future results.
Are Korsana Biosciences and Stoke Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.